PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Julia:ReplicateBE – release 0.2.0

Опубликовано 26 октября, 201926 октября, 2019 frozencat

doiGitHub

Вот и подоспел релиз 0.2.0 для оценки параметров смешанной модели репликативного дизайна биоэквивалентности по методу С (EMA) – FDA model.

 

Рубрики: IT, Julia, Mixed Model, Биоэквивалентность

Навигация по записям

Предыдущая запись: ClinicalTrialUtilities: обзор
Следующая запись: Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180814 161053
DJI 0040
20170803 180027
20180129 140251
20180202 161946
20180131 165349
  • Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-15
  • Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 19, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-15
  • Human medicines European public assessment report (EPAR): Scenesse, afamelanotide, Date of authorisation: 22/12/2014, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-15
  • Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 27, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-15
  • GDUFA Paid Facilities List
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-15 By FDA
  • PDUFA and BsUFA Quarterly Hiring Updates
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-14 By FDA
  • Patient Listening Session Summaries
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-14 By FDA
  • Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Announcement - 06/14/2022
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-14 By FDA
  • Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Announcement - 12/10/2020
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-14 By FDA
  • Vaccines and Related Biological Products Advisory Committee May 22, 2025 Meeting Announcement - 05/22/2025
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-14 By FDA
  • Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Cefazolin for Injection Due to Product Mispackaging
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-14 By FDA
  • Nostrum Laboratories, Inc. Issues Voluntary Nationwide Recall of Sucralfate Tablets USP 1 Gram Within Expiry
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-14 By FDA
  • Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-14
  • Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-14
  • Human medicines European public assessment report (EPAR): Evrysdi, risdiplam, Date of authorisation: 26/03/2021, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-14
Предыдущие записи
Тема: Scaffold от Danny Cooper.